Instrument Inactif

Autres langues VentriPoint Diagnostics Ltd. Toronto S.E.

Actions

VPT

CA92281P2008

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect	24/06
Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director	13/06
Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management	13/06
Ventripoint Diagnostics Announces Shareholder Update and Teleconference	11/06
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration	06/05
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration	06/05
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology	01/05
Duke University Health Center -- One of America's Top Heart-care Institutions and Innovators -- Purchases Ventripoint's AI Heart-scan Technology	01/05
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding	11/04
Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call	28/03
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2)	04/03
Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use	04/03
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences	20/02
Ventripoint Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences	20/02
Ventripoint Announces Changes to The Board of Directors	13/02
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO	05/02
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President	05/02
Ventripoint Begins 2024 with Leadership Change	05/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues VentriPoint Diagnostics Ltd. Toronto S.E.

Actions

VPT

CA92281P2008

Autres langues

Filtres